Business UpdateJun 2, 2026, 04:46 PM
Arvinas Reprioritizes Portfolio, Seeks Out-Licensing for ARV-806
AI Summary
Arvinas, Inc. announced a strategic reprioritization of its portfolio, including plans to seek an out-licensing agreement for ARV-806 for any additional clinical trials beyond the ongoing Phase 1 monotherapy dose escalation. The company intends to complete the Phase 1 trial and share clinical data in 2026. Arvinas also affirmed that its cash, cash equivalents, and marketable securities as of March 31, 2026, are sufficient to fund operations into the second half of 2028. An Investor Presentation will be used at upcoming meetings, including the Jefferies Global Healthcare Conference.
Key Highlights
- Arvinas decided to re-prioritize its portfolio following a strategic review.
- Company plans to complete the Phase 1 monotherapy dose escalation clinical trial for ARV-806.
- Clinical data from the ARV-806 Phase 1 trial is expected to be shared in 2026.
- Arvinas plans to seek an out-licensing agreement for further ARV-806 clinical trials.
- Cash, cash equivalents, and marketable securities as of March 31, 2026, fund operations into H2 2028.
- Company representatives will use an Investor Presentation at the Jefferies Global Healthcare Conference.
Price Impact
More from ARVN